Lifeboat Foundation

While many of us are still trying to figure out how to break up the monotony of self-isolation without spending countless hours in front of the television, perhaps some entertainment courtesy of Mother Nature herself might do the trick?

Aurora borealis (or Northern Lights) is one of nature’s most incredible phenomenons – and now you can livestream it directly into your living room.

Explore.org and Polar Bears International use footage from a camera located in Churchill, Manitoba, Canada, which is situated underneath the aurora oval – thought to be one of the best places on earth to view the aurora borealis.

There’s a new COVID-19 test from healthcare technology maker Abbott that looks to be the fastest yet in terms of producing results, and that can do so on the spot right at point-of-care, without requiring a round trip to a lab. This test for the novel coronavirus causing the current global pandemic has received emergency clearance for use by the U.S. Food and Drug Administration, and will begin production next week, with output of 50,000 per day possible starting next week.

The new Abbott ID NOW COVID-19 test uses the Abbott ID NOW diagnostics platform, which is essentially a lab-in-a-box that is roughly the size of a small kitchen appliance. It’s size, and the fact that it can produce either a positive result in just five minutes, or a negative one in under 15, mean that it could be a very useful means to extend coronavirus testing beyond its current availability to more places including clinics and doctor’s offices, and cut down on wait times both in terms of getting tested and receiving a diagnosis.

Unlike the rapid tests that have been used in other countries, and that received a new type of authorization under an FDA guideline that doesn’t confirm the accuracy fo the results, this rapid testing solution uses the molecular testing method, which works with saliva and mucus samples swabbed from a patient. This means that it works by identifying a portion of the virus’ DNA in a patient, which means it’s much better at detecting the actual presence of the virus during infection, whereas other tests that search the blood for antibodies that are used in point-of-care settings can only detect antibodies, which might be present in recovered patients who don’t actively have the virus.

Brian May is providing tutorials and a gear walkthrough for those practicing guitar in self-isolation.

Small interfering RNA (siRNA) is a powerful tool for gene silencing that has been used for a wide range of biomedical applications, but there are many challenges facing its therapeutic use in vivo. Here, we report on a platelet cell membrane–coated metal-organic framework (MOF) nanodelivery platform for the targeted delivery of siRNA in vivo. The MOF core is capable of high loading yields, and its pH sensitivity enables endosomal disruption upon cellular uptake. The cell membrane coating provides a natural means of biointerfacing with disease substrates. It is shown that high silencing efficiency can be achieved in vitro against multiple target genes. Using a murine xenograft model, significant antitumor targeting and therapeutic efficacy are observed. Overall, the biomimetic nanodelivery system presented here provides an effective means of achieving gene silencing in vivo and could be used to expand the applicability of siRNA across a range of disease-relevant applications.

RNA interference (RNAi) is a naturally occurring mechanism for gene down-regulation that, since its first discovery in the late 1990s, has been widely leveraged as a tool for biological studies. Through a robust process mediated by the RNA-induced silencing complex present within the cytosol, target genes can be posttranscriptionally silenced via degradation of the corresponding mRNA. Small interfering RNAs (siRNAs) are short and well-defined double-stranded RNA molecules that can be synthetically manufactured to take advantage of the RNAi pathway. Over time, siRNAs have become an indispensable tool for validating gene function. They have also been widely explored as therapeutics for human disease , and an siRNA-based treatment for transthyretin-mediated amyloidosis was recently approved by the U.S. Food and Drug Administration.

But as we prepare for longer journeys that will return humans to the Moon and possibly send them to Mars within the near future, scientists are working hard to measure the effects of spaceflight on the human body in order to help mitigate them for those longer missions.

And just like that, the homeless were given homes! ❤.

Labour have welcomed the plan but said councils “need more support” and money to achieve it.

Here is another good reason why it’s better to assume you are a carrier and do all you can to avoid getting others sick, even if you are healthy as an ox…

As the coronavirus pandemic surges worldwide, each piece of data counts in the fight against the deadly pathogen.

But significant findings about the contagious disease are coming from an unlikely place: Iceland, the tiny Island state with a population of just 364,000 people, where authorities are testing large numbers of the population – without imposing any lockdown or curfew.

Continue reading “Coronavirus: Iceland’s mass testing finds half of carriers show no symptoms” »

At a time of unprecedented panic over the rapidly spreading COVID-19 coronavirus, several research groups are asking whether existing therapies could be repurposed in fighting the disease. And pretty much everything seems to be on the table, including melatonin, the hormone that’s sold over-the-counter as a sleep aid.

The melatonin suggestion was published Monday in the journal Cell Discovery by Cleveland Clinic researchers, who hit on the hormone after analyzing the genomes of 15 human coronaviruses. The team compared COVID-19 with the coronavirus that caused the SARS outbreak of 2003 using a technique called “network proximity analysis” to identify combinations of existing drugs that may be able to target cellular factors that allow the viruses to replicate.

The analysis turned up three potential drug combinations: melatonin plus chemotherapy drug mercaptopurine; sirolimus, most commonly used to prevent organ-transplant rejection, combined with another chemo drug, dactinomycin; and breast cancer drug toremifene plus emodin, a chemical found in plants like rhubarb.

Bosons and fermions, the two classes into which all particles—from the sub-atomic to atoms themselves—can be sorted, behave very differently under most circumstances. While identical bosons like to congregate, identical fermions tend to be antisocial. However, in one dimension—imagine particles that can only move on a line—bosons can become as stand-offish as fermions, so that no two occupy the same position. Now, new research shows that the same thing—bosons acting like fermions—can happen with their velocities. The finding adds to our fundamental understanding of quantum systems and could inform the eventual development of quantum devices.

“All particles in nature come in one of two types, depending on their ‘spin,’ a quantum property with no real analogue in classical physics,” said David Weiss, Distinguished Professor of Physics at Penn State and one of the leaders of the research team. “Bosons, whose spins are whole integers, can share the same quantum state, while fermions, whose spins are half integers, cannot. When the particles are cold or dense enough, bosons behave completely differently from fermions. Bosons form ‘Bose-Einstein condensates,’ congregating in the same quantum state. Fermions, on the other hand, fill available states one by one to form what is called a ‘Fermi sea.’”

Researchers at Penn State have now experimentally demonstrated that, when bosons expand in one dimension—the line of atoms is allowed spread out to become longer—they can form a Fermi sea. A paper describing the research appears March 27, 2020 in the journal Science.